Tim Meyer is Professor of Experimental Cancer Medicine at UCL and Honorary Consultant in Medical Oncology at the Royal Free and ULCH Hospitals.
He is Director of the NIHR Royal Fee London Clinical Research Facility. He specialises in the management of hepatocellular and leads a large portfolio of clinical trials. He is immediate past president of ILCA and is European representative on the NCI Hepatobiliary Taskforce. He has contributed to the most recent versions of ESMO and EASL guidelines for management of HCC.